Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05256381 · OUTCOME

Nanrilkefusp Alfa Concentration Profile, Cycle 1 Day 1, 30 (+/-5) Minutes After Nanrilkefusp Alfa Administration

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors · Source last updated 2025-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
ng/mL
Interval / dispersion
Full Range
Time frame
Cycle 1 Day 1, 30 (+/-5) minutes after nanrilkefusp alfa administration

Groups in this outcome

Non-small Cell Lung Cancer

Advanced and/or metastatic non-small cell lung cancer with disease progression on or after an immune checkpoint inhibitor-containing regimen and a platinum-containing regimen, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations, and who were not amenable to curative treatment

Colorectal Cancer

Microsatellite instability-high or mismatch repair deficient colorectal cancer that was unresectable or metastatic

Cutaneous Squamous Cell Carcinoma

Recurrent or metastatic cutaneous squamous cell carcinoma that was not curable by surgery or radiation and in second line if refractory or relapsed after a checkpoint inhibitor-containing regimen and radiotherapy was not feasible

Hepatocellular Carcinoma

Advanced hepatocellular carcinoma after recurrence or failure of an immune checkpoint inhibitor (not applicable in France)

Metastatic Castration-resistant Prostate Cancer

Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent

Ovarian Cancer

Advanced recurrent ovarian cancer after recurrence or failure on the last platinum-based therapy within 6 months

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Non-small Cell Lung Cancer37
Colorectal Cancer8
Cutaneous Squamous Cell Carcinoma12
Hepatocellular Carcinoma12
Metastatic Castration-resistant Prostate Cancer53
Ovarian Cancer38

Reported measurements

Source class 1
Values in ng/mL · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Non-small Cell Lung Cancer1.0900Not reported0.2603.850Not reported
Colorectal Cancer0.5890Not reported0.4874.530Not reported
Cutaneous Squamous Cell Carcinoma0.7200Not reported0.3635.580Not reported
Hepatocellular Carcinoma0.9470Not reported0.3583.460Not reported
Metastatic Castration-resistant Prostate Cancer0Not reported04.370Not reported
Ovarian Cancer0.9020Not reported0.1513.690Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.260
        upper Limit
        3.850
        value
        1.0900
      2. group Id
        OG001
        lower Limit
        0.487
        upper Limit
        4.530
        value
        0.5890
      3. group Id
        OG002
        lower Limit
        0.363
        upper Limit
        5.580
        value
        0.7200
      4. group Id
        OG003
        lower Limit
        0.358
        upper Limit
        3.460
        value
        0.9470
      5. group Id
        OG004
        lower Limit
        0
        upper Limit
        4.370
        value
        0
      6. group Id
        OG005
        lower Limit
        0.151
        upper Limit
        3.690
        value
        0.9020
denoms
  1. counts
    1. group Id
      OG000
      value
      37
    2. group Id
      OG001
      value
      8
    3. group Id
      OG002
      value
      12
    4. group Id
      OG003
      value
      12
    5. group Id
      OG004
      value
      53
    6. group Id
      OG005
      value
      38
    units
    Participants
dispersion Type
Full Range
groups
  1. description
    Advanced and/or metastatic non-small cell lung cancer with disease progression on or after an immune checkpoint inhibitor-containing regimen and a platinum-containing regimen, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations, and who were not amenable to curative treatment
    id
    OG000
    title
    Non-small Cell Lung Cancer
  2. description
    Microsatellite instability-high or mismatch repair deficient colorectal cancer that was unresectable or metastatic
    id
    OG001
    title
    Colorectal Cancer
  3. description
    Recurrent or metastatic cutaneous squamous cell carcinoma that was not curable by surgery or radiation and in second line if refractory or relapsed after a checkpoint inhibitor-containing regimen and radiotherapy was not feasible
    id
    OG002
    title
    Cutaneous Squamous Cell Carcinoma
  4. description
    Advanced hepatocellular carcinoma after recurrence or failure of an immune checkpoint inhibitor (not applicable in France)
    id
    OG003
    title
    Hepatocellular Carcinoma
  5. description
    Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent
    id
    OG004
    title
    Metastatic Castration-resistant Prostate Cancer
  6. description
    Advanced recurrent ovarian cancer after recurrence or failure on the last platinum-based therapy within 6 months
    id
    OG005
    title
    Ovarian Cancer
param Type
MEDIAN
reporting Status
POSTED
time Frame
Cycle 1 Day 1, 30 (+/-5) minutes after nanrilkefusp alfa administration
title
Nanrilkefusp Alfa Concentration Profile, Cycle 1 Day 1, 30 (+/-5) Minutes After Nanrilkefusp Alfa Administration
type
SECONDARY
unit Of Measure
ng/mL

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice